Status: Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Participants needed: 69
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Auron Therapeutics, Inc.Updated: Sep 14, 2026Locations: 9
Eligibility criteria
Participant must be ≥18 years of age [+9]
Participant is unable to provide informed consent and/or to follow protocol requ... [+14]